Xeris Biopharma Holdings, Inc. XERS Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s tax on share settlement?
- Xeris Biopharma Holdings, Inc. (XERS) reported tax on share settlement of $17.02M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s tax on share settlement changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s tax on share settlement increased by 112.8% year-over-year, from $8M to $17.02M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s tax on share settlement?
- Over 3 years (2022 to 2025), Xeris Biopharma Holdings, Inc.'s tax on share settlement has grown at a 185.4% compound annual growth rate (CAGR), from $468K to $10.88M.
- What does tax on share settlement mean?
- Cash paid to tax authorities for employee share vesting, where the company withholds shares and pays the tax obligation in cash.